絞り込み

16573

広告

1101件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.

Afatinib-loaded Immunoliposomes Functionalized with Cetuximab: a Novel Strategy Targeting the Epidermal Growth Factor Receptor for Treatment of Non-small-cell Lung Cancer.

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib.

Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas.

Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of -mutated lung adenocarcinoma.

Diarrhea With HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis.

Banxia Xiexin Decoction () Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review.

The genomic imprint of cancer therapies helps timing the formation of metastases.

Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Modelling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.

Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.

Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります